Larimar Therapeutics
As of the edition of 20 October 2026, Larimar Therapeutics runs 3 drugs; it is on route A at 1 target and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Zafgen, Inc.: merged in 2020; successor Larimar Therapeutics, Inc.
Drugs by status
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
Where it needs a new molecule
Route A at 1 target, route B at 0 targets.
| Target | Route |
|---|---|
| METAP2 Methionine aminopeptidase 2 | Route A |
All 1 row on route A or B
In the product1 company-target row on route A or B; 0 are not shown here, and no score is.
See all 1 targets where Larimar Therapeutics needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Nutrition and metabolism: 15 trials led
- Inherited and neonatal: 8 trials led
- Nervous system: 8 trials led